Impact of Switching Treatment From Rosuvastatin to Atorvastatin on Rates of Cardiovascular Events

Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy

“…The literature on outcomes in patients who initiated or switched between branded atorvastatin and its generic version was also sparse; instead, we frequently found studies focusing on therapeutic substitution (switching between different types of statin) [85][86][87][88][89][90][91][92][93][94]. Studies that saw improved adherence with switching therapies highlighted associations with increasing age, prior CVD and polypharmacy, with the authors suggesting that patients who are switched may receive more attention at the pharmacy [95].…”

Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials

“…In the third simulated clinical trial, the effect of switching patients from rosuvastatin to atorvastatin was assessed. 45 In this trial, the virtual population was created based on the NHANES 1999–2008 data set and consisted of patients aged 45–70 years who had LDL-C levels exceeding conservative US ATP-III targets 19 after a washout period during which no lipid-lowering drugs were received (N=50,038). Subgroups assessed included patients with diabetes mellitus, those with a history of myocardial infarction or stroke, those with LDL-C levels more than double their aggressive ATP-III targets, those classified as being at moderate cardiovascular risk according to standard ATP-III guidelines, those classified as being at high cardiovascular risk according to standard ATP-III guidelines, and those whose LDL-C levels exceeded ATP-III goals after initial statin therapy.…”

Statins in Type 2 Diabetes

“…In addition, there were no differences in effects on renal function between high-dose versus low-dose. This comparison was performed in the 24 placebo-controlled trials including IDEAL [57], TNT [47], CARDS [69,70], ASPEN (The Atorvastatin Study for Prevention of coronary heart disease Endopoints in Non-diabeties mellitus) [58], SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) [43,71], and other large study using placebo with 10,345 patients with atorvastatin and 8945 patients with placebo. [43] The TNT trial in 10,001 CHD patients with and without pre-existing chronic kidney diseases demonstrated efficacy of atorvastatin (80 mg/day) on reduction of CHD risk as well as improving renal function in both with and without pre-existing renal injury patients.…”